Glucagon-like peptide-1 (GLP-1) analogues: A potential new treatment for alcohol use disorder?

Nordic Journal of Psychiatry

Volumn 70, Issue 8, 2016, Pages 561-562

  Fink Jensen, Anders ^a   Vilsbøll, Tina ^a  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

ACAMPROSATE; DIPEPTIDYL PEPTIDASE IV; DISULFIRAM; GLUCAGON; GLUCAGON LIKE PEPTIDE 1 DERIVATIVE; GLUCAGON LIKE PEPTIDE 1 RECEPTOR; NALMEFENE; NALTREXONE;

ALCOHOL ABSTINENCE; ALCOHOL CONSUMPTION; ALCOHOLISM; GLUCAGON RELEASE; GLYCEMIC CONTROL; HUMAN; NON INSULIN DEPENDENT DIABETES MELLITUS; NUCLEUS ACCUMBENS; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; VENTRAL TEGMENTUM;

EID: 84965002791     PISSN: 08039488     EISSN: 15024725     Source Type: Journal    
DOI: 10.1080/08039488.2016.1176252     Document Type: Review

References (16)

1. J.H.O'Keefe, S.K.Bhatti, A.Bajwa, J.J.DiNicolantonio, C.J.Lavie, J.H.O'Keefe,. Alcohol and cardiovascular health:the dose makes the poison or the remedy. Mayo Clin Proc 2014;89:382–93.
2. Report on Alcohol and Health. Geneva, Switzerland:World Health Organization; 2014.
3. J.Rehm, C.Mathers, S.Popova, M.Thavorncharoensap, Y.Teerawattananon, J.Patra Global burden of disease and injury and economic cost attributable to alcohol use and alcohol-use disorders. Lancet 2009;373:2223–33.
4. K.Juel, J.Sorensen, H.Bronnum-Hansen Risk factors and public health in Denmark. Scand J Public Health 2008;36:11–227.
5. M.Eliasen, U.Becker, M.Gronbaek, K.Juel, J.S.Tolstrup Alcohol-attributable and alcohol-preventable mortality in Denmark:an analysis of which intake levels contribute most to alcohol's harmful and beneficial effects. Eur J Epidemiol 2014;29:15–26.
6. A.J.Mitchell, N.Meader, V.Bird, M.Rizzo Clinical recognition and recording of alcohol disorders by clinicians in primary and secondary care:meta-analysis. Br J Psychiatry 2012;201:93–100.
7. E.Cohen, R.Feinn, A.Arias, H.R.Kranzler Alcohol treatment utilization:findings from the national epidemiologic survey on alcohol and related conditions. Drug Alcohol Depend 2007;86:214–22.
8. J.P.Connor, P.S.Haber, W.D.Hall Alcohol use disorders. Lancet 2016;387:988–98.
9. T.Vilsboll, T.Krarup, S.Madsbad, J.J.Holst Both GLP-1 and GIP are insulinotropic at basal and postprandial glucose levels and contribute nearly equally to the incretin effect of a meal in healthy subjects. Regul Pept 2003;114:115–21.
10. S.L.Dickson, R.H.Shirazi, C.Hansson, F.Bergquist, H.Nissbrandt, K.P.Skibicka The glucagon-like peptide 1 (GLP-1) analogue, exendin-4, decreases the rewarding value of food:a new role for mesolimbic GLP-1 receptors. J Neurosci 2012;32:4812–20.
11. I.Merchenthaler, M.Lane, P.Shughrue Distribution of pre-pro-glucagon and glucagon-like peptide-1 receptor messenger RNAs in the rat central nervous system. J Comp Neurol 1999;403:261–80.
12. G.F.Koob Drugs of abuse:anatomy, pharmacology and function of reward pathways. Trends Pharmacol Sci1992;13:177–84.
13. E.Egecioglu, P.Steensland, I.Fredriksson, K.Feltmann, J.A.Engel, E.Jerlhag The glucagon-like peptide 1 analogue Exendin-4 attenuates alcohol mediated behaviors in rodents. Psychoneuroendocrinology 2013;38:1259–70.
14. R.H.Shirazi, S.L.Dickson, K.P.Skibicka Gut peptide GLP-1 and its analogue, Exendin-4, decrease alcohol intake and reward. PLoS One 2013;8:e61965.
15. P.Suchankova, J.Yan, M.L.Schwandt, B.L.Stangl, E.C.Caparelli, R.Momenan,. The glucagon-like peptide-1 receptor as a potential treatment target in alcohol use disorder:evidence from human genetic association studies and a mouse model of alcohol dependence. Transl Psychiatry 2015;5:e583.
16. D.Vallöf, P.Maccioni, G.Colombo, M.Mandrapa, J.W.Jörnulf, E.Egecioglu,. The glucagon-like peptide 1 receptor agonist liraglutide attenuates the reinforcing properties of alcohol in rodents. Addict Biol 2016;21:422–37.